Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak

Canales-Albendea, M. A. (Miguel Ángel); Lázaro-Del-Campo, P. (Paula); López, A. (Andrés); Dos-Santos-Ortas, A. (Abel); Humala-Barbier, K. (Karem); Lopez-de-la-Guía, A. (Ana); Casado-Abad, G. (Gema); Jiménez-Yuste, V. (Víctor); de la Cruz-Benito, B. (Beatriz); de Soto-Álvarez, T. (Teresa); Sánchez-Vadillo, I. (Irene)

Keywords:

B cell lymphoma
COVID-19
SARS-CoV-2
Haematological malignancies
High-grade

Issue Date:

2020

Publisher Version:

https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.17066

Note:

Citation:

Canales-Albendea, M. (Miguel); Lázaro-Del-Campo, P. (Paula); Ramírez-López, A. (Andrés); et al. "Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak". British Journal of Haematology. 191 (3), 2020, 386 - 389

Abstract

The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome.

URI:

https://hdl.handle.net/10171/68602

Appears in Collections:

DA - CUN - Hematología y Hemoterapia - Artículos de revista

Files in This Item: